# Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

> **NCT00994214** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 109 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** BIM 23A760

## Key facts

- **NCT ID:** NCT00994214
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 109 (ACTUAL)
- **Why stopped:** Preliminary data from this study does not support expected inhibition of GH and IGF-1
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994214, "Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00994214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*